ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 14.37 USD 4.81% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
ARS Pharmaceuticals Inc?
Write Note

ARS Pharmaceuticals Inc
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ARS Pharmaceuticals Inc
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Accumulated Depreciation
-$121k
CAGR 3-Years
61%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accumulated Depreciation
-$7.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ARS Pharmaceuticals Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, California and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is developing neffy (previously referred to ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type 1 allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The firm has designed and developed neffy to provide injection-like absorption of epinephrine, in a small nasal spray device.

SPRY Intrinsic Value
15.37 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is ARS Pharmaceuticals Inc's Accumulated Depreciation?
Accumulated Depreciation
-121k USD

Based on the financial report for Dec 31, 2023, ARS Pharmaceuticals Inc's Accumulated Depreciation amounts to -121k USD.

What is ARS Pharmaceuticals Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
33%

The average annual Accumulated Depreciation growth rates for ARS Pharmaceuticals Inc have been 61% over the past three years , 33% over the past five years .

Back to Top